A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Advanced Cancer
BIOLOGICAL: BMS-986249|BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab
Incidence of Adverse Events (AEs), Up to 2.5 years|Incidence of Serious Adverse Events (SAEs), Up to 2.5 years|Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria, Up to 2.5 years|Incidence of AEs leading to discontinuation, Up to 2.5 years|Incidence of death, Up to 4 years|Number of participants with laboratory abnormalities, Up to 2.5 years|Incidence of treatment-related Grade 3-5 AEs, Within 24 weeks|Objective Response Rate (ORR) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to 2.5 years
Cmax (Maximum observed serum concentration), Up to 2 years|Tmax (Time of maximum observed concentration), Up to 2 years|AUC(0-T) (Area under the serum concentration-time curve from time zero to time of last quantifiable concentration), Up to 2 years|ORR as assessed by investigator using RECIST v1.1 or Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), Up to 4 years|Duration of response (DOR) as assessed by investigator using RECIST v1.1 or PCWG3 (for prostate cancer), Up to 4 years|Progression-Free survival (PFS) as assessed by investigator using RECIST v1.1 or PCWG3 (for prostate cancer), Up to 4 years|Time to response (TTR) as assessed by investigator using RECIST v1.1 or PCWG3 (for prostate cancer), Up to 4 years|Incidence of AEs in Part 2 of Study, Up to 2.5 years|Incidence of SAEs in Part 2 of Study, Up to 2.5 years|Incidence of AEs leading to discontinuation in Part 2 of study, Up to 2.5 years|Incidence of death in Part 2 of study, Up to 4 years|Number of participants with clinical laboratory abnormalities Part 2 of study, Up to 2.5 years|Time to Deterioration (TTD) in Part 2 of study, Up to 4 Years
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors